Global law firm Freshfields has advised Grünenthal Pharma GmbH & Co. KG on its €600m amend and extend financing transaction. The financing is provided by an international banking syndicate and the transaction provides for an upsize and extension of Grünenthal’s existing revolving credit facility. In addition, Freshfields has advised the initial purchasers on Grünenthal’s offering of €500m 4.625% senior secured notes due 2031.

Grünenthal is a global leader in pain management and related diseases. As a science-based, fully integrated pharmaceutical company, it has a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide.

The amend and extend financing transaction was led by Partners Michael Josenhans and Frank Laudenklos, Counsel Alexander Pospisil, Principal Associate Lucas Lengersdorf, and Associate Alexander Bräuer (all Finance, Frankfurt). The high yield bond offering was led by Partner Simone Bono, Senior Associate Shruti Dusaj, and Associates Enzo Paganetti and Chen Yan (all Leveraged Finance, London). German law advice was provided by Partner Christoph Gleske and Principal Associate Andreas Thümmler (both Finance, Frankfurt). Italian law advice was provided by Partners Francesco Lombardo (Finance) and Renato Paternollo (Tax), Counsels Giuliano Marzi (Finance) and Toni Marciante (Tax), and Senior Associate Costanza Cascone (Tax, all Milan).

Freshfields again worked closely with Grünenthal's in-house team, led by Sebastian Köhler (General Counsel) and including Sabine König (Senior Legal Counsel), Megan Renze (Senior Legal Counsel US) and Hannah Engels (Global Compliance & Responsibility Officer).